参考文献
[1] 陈莎莎,李捷,李飞,等. 2024年经导管主动脉瓣置换术年度报告[J/OL]中华心脏与心律电子杂志,2025,13(2):65‑72. DOI:10.3877/cma.j.issn.2095‑6568.2025.02.001. https://rs.yiigle.com/cmaid/1551061.
[2] Zlotorowicz M, Czubak‑Wrzosek M, Wrzosek P, et al. The origin of the medial femoral circumflex artery, lateral femoral circumflex artery and obturator artery[J]. Surg Radiol Anat, 2018, 40(5):515‑520. DOI: 10.1007/s00276‑018‑2012‑6.
[3] Tzouma G, Kopanakis NA, Tsakotos G, et al. Anatomic variations of the deep femoral artery and its branches: clinical implications on anterolateral thigh harvesting[J]. Cureus, 2020, 12(4):e7867. DOI: 10.7759/cureus.7867.
[4] Manjappa T, Prasanna LC. Anatomical variations of the profunda femoris artery and its branches‑a cadaveric study in South Indian population[J]. Indian J Surg, 2014, 76(4):288‑292. DOI: 10.1007/s12262‑012‑0677‑3.
[5] Jolly SS, AlRashidi S, d′Entremont MA, et al. Routine ultrasonography guidance for femoral vascular access for cardiac procedures: the UNIVERSAL randomized clinical trial[J]. JAMA Cardiol, 2022, 7(11):1110‑1118. DOI: 10.1001/jamacardio.2022.3399.
[6] Meijers TA, Nap A, Aminian A, et al. Ultrasound‑guided versus fluoroscopy‑guided large‑bore femoral access in PCI of complex coronary lesions: the international, multicentre, randomised ULTRACOLOR Trial[J]. EuroIntervention, 2024, 20(14):e876‑e886. DOI: 10.4244/EIJ‑D‑24‑00089.
[7] Seto AH, Abu‑Fadel MS, Sparling JM, et al. Real‑time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (femoral arterial access with ultrasound trial)[J]. JACC Cardiovasc Interv, 2010, 3(7):751‑758. DOI: 10.1016/j.jcin.2010.04.015.
[8] Wacker F, Wolf KJ, Fobbe F. Percutaneous vascular access guided by color duplex sonography[J]. Eur Radiol, 1997, 7(9):1501‑1504. DOI: 10.1007/s003300050324.
[9] Grier D, Hartnell G. Percutaneous femoral artery puncture: practice and anatomy[J]. Br J Radiol,1990,63(752):602‑604. DOI: 10.1259/0007‑1285‑63‑752‑602.
[10] Vegas A, Wells B, Braum P, et al. Guidelines for performing ultrasound‑guided vascular cannulation: recommendations of the American Society of Echocardiography[J]. J Am Soc Echocardiogr, 2025, 38(2):57‑91. DOI: 10.1016/j.echo.2024.12.004.
[11] Minici R, Serra R, Maglia C, et al. Efficacy and safety of Axiostat® hemostatic dressing in aiding manual compression closure of the femoral arterial access site in patients undergoing endovascular treatments: a preliminary clinical experience in two centers[J]. J Pers Med, 2023, 13(5):812. DOI: 10.3390/jpm13050812.
[12] Marquis‑Gravel G, Boivin‑Proulx LA, Huang Z, et al. Femoral vascular closure devices and bleeding, hemostasis, and ambulation following percutaneous coronary intervention[J]. J Am Heart Assoc, 2023, 12(1):e025666. DOI: 10.1161/JAHA.122.025666.
[13] Tabaja C, Hight N, Younis A, et al. Vascular access complications after catheter ablation of ventricular arrhythmias: Impact of vascular closure devices[J]. Heart Rhythm, 2025, 22(3):685‑692. DOI: 10.1016/j.hrthm.2024.09.001.
[14] Logemann T, Luetmer P, Kaliebe J, et al. Two versus six hours of bed rest following left‑sided cardiac catheterization and a meta‑analysis of early ambulation trials[J]. Am J Cardiol,1999,84(4):486‑488. DOI: 10.1016/s0002‑9149(99)00344‑6.
[15] Spiliopoulos S, Prountzos S, Grigoriadis S, et al. ESR essentials: arterial vascular access and closure devices‑practice recommendations by the Cardiovascular and Interventional Radiological Society of Europe[J]. Eur Radiol, 2025, 35(4):1858‑1867. DOI: 10.1007/s00330‑024‑11053‑3.
[16] Hosseini M, Lahr BD, Greason KL, et al. Obesity and vascular complication in percutaneous transfemoral transcatheter aortic valve insertion[J]. Catheter Cardiovasc Interv, 2023, 101(7):1221‑1228. DOI: 10.1002/ccd.30658.
[17] Cheng TW, Farber A, King EG, et al. Access site complications are uncommon with vascular closure devices or manual compression after lower extremity revascularization[J]. J Vasc Surg, 2022, 76(3):788‑796. DOI: 10.1016/j.jvs.2022.03.890.
[18] Henry JC, Franz RW. Pseudoaneurysms of the peripheral arteries[J]. Int J Angiol, 2019, 28(1):20‑24. DOI: 10.1055/s‑0039‑1677676.
[19] Jipa AM, Makary MS. Access site femoral arterial pseudoaneurysm[J]. J Vasc Interv Radiol, 2024, 35(4):629‑630. DOI: 10.1016/j.jvir.2023.12.570.
[20] Stolt M, Braun‑Dullaeus R, Herold J. Do not underestimate the femoral pseudoaneurysm[J]. Vasa,2018,47(3):177‑185. DOI: 10.1024/0301‑1526/a000691.
[21] 刘淼, 钱朝庆. 超声引导下股动脉假性动脉瘤凝血酶注射和血管腔内缝合临床对比[J]. 中国超声医学杂志, 2024, 40(11):1304‑1307. DOI: 10.3969/j.issn.1002‑0101.2024.11.032.
[22] Xiang DC, Hillegass WB, Luo GX, et al. Treatment of refractory iatrogenic femoral artery pseudoaneurysm with a vascular closure device[J]. J Vasc Interv Radiol, 2009, 20(12):1639‑1640. DOI: 10.1016/j.jvir.2009.08.023.
[23] Janák D, Rohn V. Retroperitoneal hematoma: diagnosis and treatment[J]. Rozhl Chir, 2022, 100(12):569‑575. DOI: 10.33699/PIS.2021.100.12.569-575.
[24] 郑波,李兆南,袁罡,等. 股动脉穿刺并发股神经损伤相关因素分析 [J]. 介入放射学杂志,2018,27(10): 963‑965. DOI:10.3969/j.issn.1008‑794X.2018.10.013.
[25] Safian RD. Current approaches to retroperitoneal hemorrhage: Too little, too late[J]. Catheter Cardiovasc Interv, 2017, 90(1):112‑113. DOI: 10.1002/ccd.27168.
[26] Redondo Villatoro A, Azcona Sutil L, Vargas Gálvez D, et al. Diagnosis and management of postpartum retroperitoneal hematoma: a report of 3 cases[J]. Am J Case Rep, 2022, 23:e935787. DOI: 10.12659/AJCR.935787.
[27] Kamber HM, Al‑Marzooq T, Neamah HR, et al. Outcomes of operative management of 96 cases with traumatic retroperitoneal hematoma: a single‑institution experience[J]. Open Access Maced J Med Sci, 2018, 6(11):2128‑2132. DOI: 10.3889/oamjms.2018.437.
[28] Malík J, Holaj R, Krupičková Z, et al. Arteriovenous fistula after femoral artery puncture leading to pulmonary edema: the role of ultrasonography[J]. Prague Med Rep, 2012, 113(1):49‑52. DOI: 10.14712/23362936.2015.56.
[29] Lee E, Tirukonda PS, Tan A, et al. Clinics in diagnostic imaging (206). Arterioureteral fistula (AUF)[J]. Singapore Med J, 2020, 61(6):327‑330. DOI: 10.11622/smedj.2020089.
[30] Onal B, Kosar S, Gumus T, et al. Postcatheterization femoral arteriovenous fistulas: endovascular treatment with stent‑grafts[J]. Cardiovasc Intervent Radiol, 2004, 27(5):453‑458. DOI: 10.1007/s00270‑004‑0176‑4.
[31] Thalhammer C, Kirchherr AS, Uhlich F, et al. Postcatheterization pseudoaneurysms and arteriovenous fistulas: repair with percutaneous implantation of endovascular covered stents[J]. Radiology, 2000, 214(1):127‑131. DOI: 10.1148/radiology.214.1.r00ja04127.
[32] Ding WY, Khanra D, Kozhuharov N, et al. Incidence of vascular complications for electrophysiology procedures in the ultrasound era: a single‑centre experience over 10,000 procedures in the long term[J]. J Interv Card Electrophysiol,2023,66(3):693‑700. DOI: 10.1007/s10840‑022‑01386‑8.
[33] Al‑Momani MS, AbuRuz ME. Incidence and predictors of groin complications early after coronary artery intervention: a prospective observational study[J]. BMC Nurs,2019,18:24. DOI: 10.1186/s12912‑019‑0349‑8.
[34] Khidher BO, Al‑Aqeedy RF. Incidence and risk factors of femoral Access‑Site hematoma following cardiac catheterization: a six‑month observational study from Erbil cardiac center[J]. Perinatal Journal, 2026, 34(1): 485‑492. DOI: 10.57239/prn.26.03410051.
[35] Jiang J, Zou J, Ma H, et al. Network meta‑analysis of randomized trials on the safety of vascular closure devices for femoral arterial puncture site haemostasis[J]. Sci Rep, 2015,5:13761. DOI: 10.1038/srep13761.
[36] Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long‑term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005[J]. JACC Cardiovasc Interv,2008,1(2):202‑209. DOI: 10.1016/j.jcin.2007.12.006.
[37] Ricci MA, Trevisani GT, Pilcher DB. Vascular complications of cardiac catheterization[J]. Am J Surg, 1994, 167(4):375‑378. DOI: 10.1016/0002‑9610(94)90119‑8.
[38] Prasad A, Compton PA, Prasad A, et al. Incidence and treatment of arterial access dissections occurring during cardiac catheterization[J]. J Interv Cardiol, 2008, 21(1):61‑66. DOI: 10.1111/j.1540‑8183.2007.00309.x.
[39] Thieme M, Moebius‑Winkler S, Franz M, et al. Interventional treatment of access site complications during transfemoral TAVI: A single center experience[J]. Front Cardiovasc Med, 2021,8:725079. DOI: 10.3389/fcvm.2021.725079.
[40] 任伟, 王志维, 吴智勇, 等. 合并急性下肢缺血的Stanford A型主动脉夹层的临床疗效分析[J]. 中华胸心血管外科杂志, 2019, 35(3):154‑158. DOI: 10.3760/cma.j.issn.1001‑4497.2019.03.007.
[41] Zhang R, Wei H, Ren Y, et al. Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China[J]. Front Neurol, 2021,12:685454. DOI: 10.3389/fneur.2021.685454.
[42] 许立庆, 刘志, 李博宇, 等. 冠状动脉血栓内注射溶栓药对急性心肌梗死疗效的影响[J]. 中华保健医学杂志, 2012, 14(4):283‑285. DOI: 10.3969/j.issn.1674‑3245.2012.04.008.
[43] Tsetis DK, Kochiadakis GE, Hatzidakis AA, et al. Transcatheter thrombolysis with high‑dose bolus tissue plasminogen activator in iatrogenic arterial occlusion after femoral arterial catheterization[J]. Cardiovasc Intervent Radiol, 2002, 25(1):36‑41. DOI: 10.1007/s00270‑001‑0061‑3.
[44] Braithwaite BD,Buckenham TM,Galland RB,et al. Prospective randomized trial of high‑dose bolus versus low‑dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group [J]. Br J Surg,1997,84(5): 646‑650.
[45] 国家心血管病专家委员会血管外科专业委员会下肢动脉疾病学组,中国医药教育协会血管外科专业委员会. 股腘动脉闭塞症的诊断和治疗中国专家共识 [J]. 中国循环杂志,2022,37(7): 669‑676. DOI:10.3969/j.issn.1000‑3614.2022.07.003.
[46] Noori VJ, Eldrup‑Jørgensen J. A systematic review of vascular closure devices for femoral artery puncture sites[J]. J Vasc Surg, 2018, 68(3):887‑899. DOI: 10.1016/j.jvs.2018.05.019.
[47] Gonze MD, Sternbergh WC, Salartash K, et al. Complications associated with percutaneous closure devices[J]. Am J Surg, 1999, 178(3):209‑211. DOI: 10.1016/s0002‑9610(99)00143‑9.